Home Health & Medical Health Pharmaceutical Chemicals Amino Acids and Coenzymes

Hormones

faceboox pinterest twitter share

Negotiable Min Order Quantity Unit

Required Quantity

Place of Origin

Payment Terms: Negotiable

Production method: Negotiable

Shipping / Lead Time: Negotiable / Negotiable

Keyword

Category: Amino Acids and Coenzymes

SEND TO SUPPLIER INQUIRY

Myungmoon Pharm. Co., Ltd.

Country / Year Established: South Korea /

Business type: Others

Verified Certificate

TRADE TOWER

DUNS

Minisite Follow Company

PRODUCT DESCRIPTION COMPANY INFORMATION Related Products

Product name	Hormones	Certification	-
Category	Amino Acids and Coenzymes	Ingredients	-
Keyword	-	Unit Size	-
Brand name	-	Unit Weigh	-
origin		Stock	-
Supply type	-	HS code	-

Product Information

Esdiol half Tab.(Estradiol hemihydrate 1.03mg, Norethisterone acetaet 0.5mg)

Composition : One tablet contains
Estradiol hemihydrate - 1.03mg
Norethisterone acetate - 0.5mg

Indication & Usage :

Treatment of moderate to severe vasomotor symptoms associated with the menopause
Treatment of vulvar and vaginal atrophy
Prevention of postmenopausal osteoporosis
Refer to insert-paper for further information

Dosage & Administration :

Esdiol-Half therapy consists of a single tablet to be taken once daily.
Refer to insert-paper for further information

Package : 28 Tablets

Esgen Tab.(Estropipate 0.75mg, 1.5mg)

Composition : One tablet contains
Estropipate - 0.75mg(Sodium estrone sulfate 0.625mg)
Estropipate - 1.5mg(Sodium estrone sulfate 1.25mg)

Indication & Usage, Dosage & Administration

Treatment of moderate to severe vasomotor symptoms associated with the menopause.
Treatment of vulval and vaginal atrophy
Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure
Prevention of osteoporosis

Package : 0.625mg/Tab x 500, 300Tab(PTP), 1.25mg/Tab x 500

Esgen Vaginal Cream(Estropipate 1.5mg/g)

Composition : 1g contains
Estropipate - 1.5mg

Indication & Usage : Atrophic vaginitis and vulvar atrophy

Dosage & Administration :
Intravaginal, 2 to 4mg of estropipate daily

Package : 15g/Tube, 42.5g/Tube

Libron Tab.(Tibolone 2.5mg)

Composition : One tablet contains
Tibolone - 2.5mg

Indication & Usage :

Symptomatic treatment of hot flushes and associated sweating resulting from the natural or surgical menopause.
Prevention of postmenopausal osteoporosis.

Dosage & Administration

The dosage is one tablet per day.
Refer to insert-paper for further information

Package : 300 Tablets

Progen Tab.(Medroxyprogesterone acetate 2.5mg/5mg/10mg)

Composition : One tablet contains
Medroxyprogesterone acetate - 2.5mg
Medroxyprogesterone acetate - 5mg
Medroxyprogesterone acetate - 10mg

Indication & Usage :

Secondary amenorrhea
Abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.
Endometriosis of indisposition or moderate.
Concomitant medication with estrogen associated with menopause women who is not practice the hysterectomy.

Package
- 2.5mg/Tab x 300, 300Tab(P.T.P)
- 5mg/Tab x 300,
- 10mg/Tab x 300

B2B Trade

Price (FOB)	Negotiable	transportation	-
MOQ	Negotiable	Leadtime	Negotiable
Payment Options	Negotiable	Shipping time	Negotiable

Myungmoon Pharm. Co., Ltd.

Minisite Heart

Country / Year Established: South Korea /

Business type: Others

TRADE TOWER

DUNS

President: LEE, GYU HUOK

Address: Myungmoon B/D, 946-18, Dokok-Dong, Gangnam-Ku, Korea

Product Category: Beauty & Personal Care,Chemical & Pharmaceutical Machinery,Pharmaceuticals

No. of Total Employees: 101-500

Company introduction: In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation. Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.

Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and generalmedicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.

Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, however, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future. To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.

Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.